Arvinas Inc (ARVN): Price Now Near $84.83; Daily Chart Shows An Uptrend on 100 Day Basis

The Hourly View for ARVN

At the time of this writing, ARVN (Get Ratings)’s price is down $-0.62 (-0.73%) from the hour prior. It’s been a feast for bears operating on an hourly timeframe, as ARVN has now gone down 4 of the past 5 hours. As for the trend on the hourly timeframe, we see the clearest trend on the 50 hour timeframe. Most noteworthy in the world of moving averages on the hourly chart is that the 100 and 50 hour moving averages have been crossed, so that price is now turning below them. The moving averages on the hourly timeframe suggest a choppiness in price, as the 20, 50, 100 and 200 are all in a mixed alignment — meaning the trend across timeframes is inconsistent, indicating a potential opportunity for rangebound traders.

ARVN ranks 273rd in terms of today’s price percentage change out of Pharmaceutical Products stocks.

ARVN’s Technical Outlook on the Daily Chart

At the moment, ARVN’s price is down $-0.52 (-0.6%) from the day prior. This is the 2nd day in a row ARVN has seen its price head down. As for the trend on the daily timeframe, we see the clearest trend on the 100 day timeframe. The moving averages on the daily timeframe suggest a bullishness in price, as the 20, 50, 100 and 200 are all in a bullish alignment — meaning the shorter durations are above the longer duration averages, implying a sound upward trend. Arvinas Inc’s price action over the past 90 days can be seen via the chart below.



ARVN: Daily RSI Analysis

  • ARVN’s RSI now stands at 42.4116.
  • ARVN and RSI may be exhibiting divergent trends. This may be something to monitor.

For ARVN News Traders

News traders keeping an eye on ARVN may find value in this recent story:

Arvinas to Participate in Upcoming Virtual Investor Conferences

NEW HAVEN, Conn., Sept. 01, 2021 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences: Citi 16th Annual BioPharma Virtual Conference on Thursday, September 9, 2021. John Houston, Ph.D., President and Chief Executive Officer, and Ron Peck, M.D., Chief Medical Officer, will participate in a fireside chat at 9:

Want More Great Investing Ideas?

9 “MUST OWN” Growth Stocks for 2021

5 WINNING Stock Chart Patterns

7 Best ETFs for the NEXT Bull Market